

# ePosterboard Presenter-Board Assignments

2019 Alliance Fall Group Meeting | November 7-9 - Loews Chicago O'Hare Hotel (Rosemont, IL)



ePoster Kiosk #1 Breast Trials		
Study #	Title	Author
A011104	Effect of preoperative breast MRI on surgical outcomes, costs and quality of life of women with breast cancer	I. Bedrosian
A011401	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (BWEL)	J. Ligibel
A011502	A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer: The ABC trial	W. Chen
ePoster Kiosk #2		
AFT-05/PALLAS	Palbociclib collaborative adjuvant study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive/HER2-negative breast cancer	E. Mayer
AFT-38/PATINA	A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer	O. Metzger
ePoster Kiosk #3 CDDR (Cancer Care Delivery Research) Trials		
A231601CD	Improving surgical care and outcomes in older cancer patients through implementation of an efficient pre-surgical toolkit (OPTI-Surg)	G. Chang
A231701CD	Increasing socioeco disadvan pts' engagement in breast ca tx decision making	H. Neuman
AFT-39	Patient -reported outcomes to enhance cancer treatment trial (PRO-TECT)	E. Basch
ePoster Kiosk #4 Cancer Care Delivery Research (CDDR) Trials		
AFT-16	Phase II trial of induction immunotherapy+C72:C93 with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent	H. Ross
AFT-28	DOACS versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial	J. Connors and D. Schrag
AFT-25	Comparison of operative to monitoring and endocrine therapy for low-risk DCIS	S. Hwang
ePoster Kiosk #5 Cancer in the Older Adult and Experimental Therapeutics Trials		
A171603	Feasibility of an electronic geriatric assessment (eGA) for older adults with cancer	A. Jatoi
A091802	Phase II randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma of the skin (cSCC)	D. Zandberg
A091605	A randomized phase II study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced Merkel cell carcinoma	J. Luke
ePoster Kiosk #6 Gastrointestinal (GI) Trials and Genitourinary (GU) Trials		
A021502	Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair	F. Sinicrope
A021602	Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus	J. Chan
A031102	A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)	D. Feldman
A031501	Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) vs observation	A. Apolo
ePoster Kiosk #7 Genitourinary (GU) Trials		
A031701	A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations	G. Iyer
A031702	A phase II study of ipilimumab, cabozantinib, and nivolumab in rare genitourinary cancers (ICONIC)	A. Apolo
A031704	PD-inhibitor (nivolumab) and ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: A phase III trial in metastatic untreated renal cell cancer (PDIGREE)	T. Zhang
AFT-19	A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer	R. Aggarwal

ePoster Kiosk #8 Leukemia Trials		
A041501	A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL	D. DeAngelo
A041701	A randomized phase II/III study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy	G. Uy
A041702	A randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (>= 70 years of age) with chronic lymphocytic leukemia (CLL)	J. Woyach
ePoster Kiosk #9 Lymphoma Trial and Myeloma Trials		
AFT-15	A phase I study of ibrutinib (PCI-32765) in combination with revlimid/dexamethasone (Rd) in relapsed/refractory multiple myeloma	J. Laubach
AFT-32	A phase II study of palbociclib (PD-0322991) in combination with ibrutinib in patients with previously treated mantle cell lymphoma	K. Maddocks
ePoster Kiosk #10 Neuro-Oncology Trials		
A071601	Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas	P. Brastianos
A071701	Genomically-guided treatment trial in brain metastases	P. Brastianos
N0577	Phase III intergroup study of temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low grade glioma	K. Jaeckle
ePoster Kiosk #11 Respiratory Trials		
A081105	Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)	R. Govindan
A151216	Adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST)	G. Oxnard
CALGB-30610	Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide	J. Bogart
ePoster Kiosk #12 Respiratory Trials		
AFT-09/ Pembrolizumab	A randomized phase II trial evaluating the optimal sequencing of PD-1 inhibition with pembrolizumab (MK-3475) and standard platinum-based chemotherapy in patients with chemotherapy naive stage IV non-small cell lung cancer	T. Hensing
AFT 42	Safety, activity, and pharmacology of nivolumab in patients with advanced non-small cell lung cancer and pre-existing autoimmune disease	Heist
ePoster Kiosk #13 Prevention Trials		
A211102	Testing for atypia in random periareolar fine needle aspiration (RPFNA) cytology after 12 months metformin (1,1-dimethylbiguanide hydrochloride) chemoprevention versus placebo control in premenopausal women	V. Seewaldt
A211401	Reducing surgical complications in newly diagnosed lung cancer patients who smoke cigarettes	I. Croghan
A211601	Evaluation of mammographic breast density effect of aspirin: A companion to Alliance study A011502	M. Wood
A211701	A prospective study to establish a new onset diabetes cohort	S. Chari
ePoster Kiosk #14 Symptom Intervention Trials		
A221405	A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy	A. Partridge
A221504	A randomized, double-blind, placebo-controlled pilot study of an oral, selective peripheral opioid receptor antagonist in advanced non-small cell lung cancer (adenocarcinoma)	P.Gupta
A221505	Phase III randomized trial of hypofractionated post mastectomy radiation with breast reconstruction	M. Poppe
A221702	Axillary Reverse Mapping: A prospective trial to study rates of lymphedema and regional recurrence after sentinel lymph node biopsy and sentinel lymph node biopsy followed by axillary lymph node dissection with and without axillary reverse mapping (ARM)	V. Klimberg
ePoster Kiosk #15 Symptom Intervention Trials and Health Outcomes Trial		
A221602	Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A phase III randomized, double blind, placebo controlled trial	R. Navari
A221701	Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches	K. Ruddy and H. Rugo